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Pregnancy Associated Mouse Protein 1 (PAMPI) was isolated from plasma of female mice. An antiserum raised against the purified protein 
confirmed its immunochemical identity with the originally described PAMPl. Pregnant females were observed to have plasma levels of PAMPl 
that are increased two-fold at day lo-13 of gestation relative to non-pregnant females, while male mouse plasma did not contain PAMPl. The 
purified protein displayed an apparent subunit molecular mass of 70 kDa, irrespective of cystine reduction. The native molecular mass, estimated 
by gel-filtration, was about 140 kDa, indicating that PAMPl is circulating as a non-covalent homodimer. The amino-terminal sequence of the intact 
protein and the internal sequences of four cyanogen bromide fragments demonstrated that this protein is not related to any known member of 
the ~-2-macroglobulin family nor to any protein in the sequence databases. The physic~hemi~al nd the sequence data thus establish this protein 
as a novel, female-specific protein, but unrelated to the Macroglobulin proteinase inhibitor family. 
Pregnancy protein; a-2-Macroglobulin 
1. INTRODUCTION 
Pregnancy-associated proteins have been intensely 
studied, both for clinical and for fundamental reasons. 
One of these proteins, Pregnancy Associated Mouse 
Protein 1 or PAMPl, was shown by immunochemical 
means to be a possible murine counterpart of the human 
Pregnancy Zone Protein (PZP) [l--I]. PZP is a pro- 
teinase inhibitor and scavenger of the a-2-macroglob- 
ulin (AZM) family [5-71. Expression of PZP is normally 
restricted to pregnant women with highest blood levels 
in the third trimester of pregnancy [2,8,9]. The role of 
PZP in vivo, its precise target proteinases or other scav- 
enger functions, remains enigmatic in view of the al- 
ready abundant presence of A2M, the constitutional 
wide-spectrum proteinase scavenger in humans [7, lo]. 
Since neither the site of synthesis of PZP nor the factors 
regulating its synthesis are known and since no human 
cell lines secreting PZP are available, an animal model 
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system would be an important alternative to the human 
system. 
Since we are engaged in the characterization of the 
murine A2M family of proteinase inhibitors and their 
receptor [1 l-161 we became interested in PAMPl as a 
possible PZP homolog. We report here the isolation of 
PAMPl from female mouse plasma and the results of 
the analysis of its main structural and physical charac- 
teristics. The findings demonstrate that this protein is 
structurally and functionally not related to A2M or 
PZP. The N-terminal and internal protein sequences 
obtained indicate it to be an unknown protein showing 
no sequence identity with any known protein. More- 
over, its presence in the plasma of female mice irrespec- 
tive of their gestational status and the virtual absence 
of PAMPl in the plasma of all male mice examined, 
leaves us to conclude that PAMPl is a female-specific 
but not a pregnancy-associated protein. 
2. MATERIALS AND METHODS 
2.1. Isolation of PAMPl from mouse plasma 
Mice from the NMRI strain were used throughout. Mouse blood 
was collected from anesthesized animals by cardiac puncture in hepar- 
inized syringues. After centrifugation the plasma (5 ml) was treated 
with polyethyleneglycol 6000 (5% final concentration). After mixing 
for 30 min at 4°C the clear supernatant, collected after centrifugation 
(8,000 x g, 30 min), was subjected to gelfiltration on a column (2.6 x 95 
cm) containing ACA 34 (LKB-Pharmacia) and developed in phos- 
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phate-buffered saline (PBS, 10 mM sodium phosphate, 0.15 M NaCI, 
pH 7.4). The peak corresponding to PAMPl was identified by rocket 
immunoelectrophoresis and fractions were pooled and concentrated. 
Subsequently, hydrophobic interaction chromatography on a TSK 
Phenyl-SPW column [17] was done to separate PAMPl from Murin- 
oglobulin, albumin and immunoglobulins. The final purification step 
consisted of high performance gelfiltration on columns (1 x 30 cm) of 
Superose-6 and Superose-12 (Pharmacia) coupled in series. Column 
fractions and pools were analyzed by SDS-PAGE and by rocket im- 
munoelectrophoresis. 
Original antisera against PAMPl were prepared by immunization 
of rabbits or goats with pregnant mouse serum and absorbed with 
male mouse sera [1,2]. These were used to monitor the purification of 
PAMPl from mouse plasma. The purified PAMPl protein was used 
to immunize rabbits to obtain monospecific polyclonal antibodies. 
Rocket immunoelectrophoresis was carried out on glass plates, in 
1% agarose gels in 89 mM Tris, 89 mM boric acid, 2 mM EDTA, pH 
8.4 (TBE) containing the specified antiserum. After electrophoresis 
(overnight at 2.5 V/cm) the gels were soaked, dried and stained with 
Coomassie brilliant blue and destained by diffusion. 
2.2. N-terminal protein sequencing 
N-terminal aminoacid microsequencing of intact proteins was done 
after binding of the protein (about 100 pmol) to Biobrene treated 
glassfilters. For cyanogen bromide fragmentation, PAMPI was dis- 
solved in 70% formic acid and treated with CNBr in a lOO-fold molar 
excess for 18 h at room temperature. After lyophilization and resus- 
pending in water (repeated three times), the residue was dissolved in 
SDS sample buffer and the peptides eparated by SDS-PAGE [11,18]. 
After electrotransfer to Problott membranes, the membranes were 
stained briefly with Coomassie brillant blue, washed exhaustively in 
water and the stained bands cut out for direct solid state sequencing 
according to the procedures of the manufacturer (Applied Biosys- 
terns). N-terminal protein microsequencing was performed on an Ap- 
plied Biosystems Model 477A pulsed liquid phase sequencer with 
on-line phenylthiohydantion-amino acid identification (Applied Bio- 
system 120A Analyser). 
3. RESULTS 
PAMPl was isolated from heparinized mouse plasma 
by a simple procedure including polyethylene glycol 
precipitation, followed by a first gelfiltration step. Sub- 
sequently, hydrophobic interaction chromatography 
(HIC-HPLC) was performed on a phenyl derivatized 
matrix (Fig. 1). PAMPl binds to this matrix under con- 
ditions (0.1 M sodium phosphate, 0.5 M sodium 
sulphate, pH 6.5) which are identical to those used for 
binding of native human A2M and PZP [6,17]. PAMPl 
is eluted from the column at the end of the gradient (Fig. 
1). Since we used water as the limiting eluent, this indi- 
cated that PAMPl is similar to native A2M and PZP 
rather hydrophobic in nature. However with all prepa- 
rations of A2M and PZP (even native protein prepara- 
tions) analyzed to date, we have observed more compli- 
cated chromatograms. This is due to inactivated and 
complexed forms of A2M and PZP which elute earlier 
in the gradient [17]. This was never observed with 
PAMPI, which eluted at the end of the gradient in a 
single peak. 
Further purification was by high performance gelfil- 
tration (Fig. 2). This also allowed us to estimate the 
native molecular mass of the protein at about 140 kDa 
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Fig. 1. Hydrophobic interaction chromatography of PAMPl. Frac- 
tions containing PAMPl were applied on a Phenyl TSK-5PW column 
in 0.1 M sodium phosphate, 0.5 M sodium sulfate, pH 6.5. After 
washing with the same buffer, a linear gradient was used to develop 
the column, at a flowrate of 1 ml/min. The limiting eluent was water 
[17]. Under these conditions PAMPl is eluted as a sharp peak at the 
end of the gradient, an elution behaviour which is very similar to that 
of native cc-2-macroglobulin [ 171. The absorbance tracing at 280 nm 
and the linear gradient profile (from O-100% water) are shown. 
(using A2M, immunoglobulin and albumin to calibrate 
the columns), identical to the reported value [2]. The 
subunit molecular mass, which to our knowledge has 
not been determined before, was estimated at 70 kDa 
under denaturing and reducing conditions (Fig. 3). 
Without cystine reduction, the apparent molecular 
weight increased only slightly to about 75 kDa (Fig. 3). 
The purified protein was used to immunize rabbits. 
The antiserum displayed a complete identity in double 
immunodiffusion tests with an antiserum originally 
used to demonstrate the existence of PAMPl [2]. The 
purified protein did not react with polyclonal antisera 
against human A2M, human PZP, mouse A2M or 
mouse Murinoglobulin. 
Rocket immunoelectrophoresis of plasma from male 
and from normal and pregnant female mice showed the 
presence of PAMPl in all female sera and its complete 
absence in plasma from male mice (Fig. 4). Normal 
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Fig. 2. High performance gelfiltration of PAMPI. Pooled fractions of 
the Phenyl-SPW column containing PAMPl were concentrated to 250 
~1 and applied on columns of Superose-6 and Superose-12 (Pharma- 
cia), coupled in series. Elution was carried out with Tris-buffered 
saline (10 mM Tris, 0.15 M NaCI, pH 7.6) at a flowrate of 0.75 mlfmin 
and fractions of 3 ml were collected. Fractions 4-6 contained pure 
PAMPl and were pooled and concentrated. 
levels of PAMPl in female mice were estimated at be- 
tween 0.2 and 0.5 pg per ml plasma, increasing to about 
double these values in mid-gestation (day 10-13). 
Aminoterminal sequencing of the purified protein 
yielded a unique sequence of 15 amino acids (Table I). 
Internal sequences were obtained after partial cyanogen 
bromide cleavage of the protein, separation of the frag- 
ments by SDS-PAGE and electroblotting. A 30 kDa 
CNBr fragment yielded the same aminoterminal se- 
quence as the intact PAMPl , while the other fragments 
yielded unique sequences. All the sequences dete~ined 
were different from N-terminal or internal protein se- 
quences of the members of the A2M family of pro- 
teinase inhibitors known to us (human A2M and PZP, 
mouse A2M and Murinoglobulin, rat AIM, A2M and 
Al inhibitor 3). Furthermore, no significant sequence 
identity was detected with any protein in the protein 
sequence database (Swissprot) nor, after reverse trans- 
lation, in the nucleotide sequence databases consulted 
(EMBL and Genbank). 
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Fig. 3. Subunit molecular mass of PAMPl. The equivalent of 5 pug 
protein was applied after denaturation with or without reduction (1% 
SDS in 50 mM Tris, pH 8.0, with or without 1% 2-mercaptoethanol 
kept at 100°C for 5 min). Lane 1: PAMPI, unreduced. Lane 2: mark- 
ers with M, as indicated. Lane 3: PAMPl, reduced. 
4. DISCUSSION 
We have isolated the mouse protein, previously iden- 
tified and named PAMPl, in order to examine its rela- 
tion to the a-Zmacroglobulin family of proteinase in- 
hibitors. This relation was originally claimed based on 
the immunochemical cross-reaction between this pro- 
tein and the human Pregnancy Zone Protein [l-3]. 
f pf m 
Fig. 4. Rocket immun~l~trophoresis of PAMPl in mouse plasma. 
Mouse plasma (m = male, f = female and pf = pregnant female) was 
diluted ten-fold in 0.15 M NaCl and 5 ~1 samples were applied in the 
wells. The gel contained 7.5% (v/v) of a polyclonal rabbit antiserum 
directed against PAMPl. A weak cross reaction with an unidentified 
plasma protein was noted in all samples, also in the male plasma 
samples. 
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Table I 
Aminoterminal protein sequences of intact PAMPl and of its cyano- 
aen bromide fragments. 
N-terminal sequence 
Intact PAMPl LMLDSGSEPKLIAEP 
CNBr fragments: 
50 kDa 
40 kDa 
35 kDa 
30 kDa 
I8 kDa 
LxPQGPYE 
LSDETLQAPV 
LNDEGTEAVFEL 
LMLDSG 
LSNAVEVTGKEPLP 
The isolated PAMPl protein was treated with CNBr and the frag- 
ments were separated by SDS-PAGE and electroblotted onto Problott 
membranes. The peptide bands were located by staining, cut out and 
used for N-terminal sequencing (see Section 2). Amino acids are de- 
noted by their one letter code (L, leucine; P, proline; Q, glutamine; G, 
glycine; P, proline; Y, tyrosine; E, glutamic acid; S, serine; D, aspartic 
acid; T, threonine; A. alanine; V, valine; N, asparagine; F, phenylalan- 
ine; M, methion~ne; K, lysine; x denotes an unidentified residue). 
The fysico-chemical characterization of the purified 
PAMPl protein yielded a subunit molecular weight of 
70 kDa, which was only marginally higher when the 
protein was analyzed unreduced. This has not been re- 
ported previously. The native molecular mass by gelfil- 
tration yielded a value of 140 kDa, similar to the re- 
ported value [2]. The N-terminal sequence obtained 
from the intact protein yielded single derivatives in each 
cycle, proving that a single species was being analyzed, 
confirming the single protein band observed in SDS- 
PAGE. Taken together these results demonstrate that 
the isolated PAMPl protein circulates in the murine 
bloodstream as a 140 kDa, non-covalent homodimer of 
70 kDa subunits. 
The molecular data and the N-terminal sequences of 
the isolated protein and of the cyanogen bromide frag- 
ments demonstrate conclusively that this protein is not 
related to the a-2-macroglobulin family of proteinase 
inhibitors. These sequences are neither related to those 
of mouse A2M [ 161 nor to any Murinoglobulin [ 121, nor 
to any protein sequence in the sequence databases con- 
sulted. 
examination of mouse sera and plasma with the an- 
tiserum obtained by immunization with the purified 
protein confirmed that PAMPl is restricted to females. 
Plasma of pregnant females showed the highest concen- 
tration around day lo-13 of gestation, with levels about 
twice normal. Normal levels in females of the NMRI 
mouse strain were estimated at 0.2-0.5 pg/ml plasma. 
Male plasma samples were negative when examined by 
rocket immunoelectrophoresis. The purified protein did 
not react with specific polyclonal antisera directed 
against human, A2M or PZP, or against mouse A2M 
or Murinoglobulin. The original observation regarding 
the immunochemical crossreaction with antisera 
against human PZP thereby remains unexplained. Our 
result do caution however against conclusions based 
solely on immunochemical findings without support of 
physico-chemical or sequence data. 
We conclude that PAMPl is not a pregnancy specific 
but a female specific protein, unrelated to A2M or to 
any known protein. We propose to rename the protein 
to FSMP or Female Specific Mouse Protein, until a 
more appropriate name, referring to the as yet unknown 
function of the protein, can be coined. 
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